Medtronic plc (NYSE: MDT), a leader in healthcare technology, presented compelling new data at the American Diabetes Association’s (ADA) 84th Scientific Sessions, highlighting the MiniMed 780G system’s efficacy in managing hyperglycemia and reducing nighttime burden for individuals with chronic inflammatory demyelinating polyneuropathy (CIDP). This data adds to the growing body of evidence that the MiniMed […]
Medtronic plc (NYSE: MDT), a global frontrunner in medical technology, has recently unveiled compelling new clinical and real-world evidence regarding the MiniMed 780G system, marking a significant advancement in diabetes management technology. Presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence, Italy, this evidence underscores the system’s efficacy […]
